Article info

Download PDFPDF

Protocol
Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial

Authors

  1. Correspondence to Dr Zhigang Zhang; zzg2011{at}zju.edu.cn
View Full Text

Citation

Zhu Y, Fei J, Zhu X, et al
Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial

Publication history

  • Received August 17, 2024
  • Accepted January 20, 2025
  • First published February 5, 2025.
Online issue publication 
February 05, 2025

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.